Bio-rad Laboratories, INC 8-K filings

Bio-Rad Laboratories stockholders approved the amended 2017 Incentive Award Plan and re-elected all director nominees at the 2026 Annual Meeting.

Bio-Rad Laboratories, Inc. disclosed key financial results for its investment in Sartorius AG for the year ended December 31, 2025.

Bio-Rad Laboratories announced modest revenue growth and strong free cash flow for 2025, but gross and operating margins fell below expectations amid challenging market conditions.

Bio-Rad Laboratories announced third-quarter 2025 financial results, reporting modest revenue growth and a better-than-expected operating margin despite market challenges.

Bio-Rad Laboratories, Inc. announced the passing of its co-founder and Director Emeritus, Alice N. Schwartz, at the age of 99.

Bio-Rad Laboratories details its Droplet Digital PCR portfolio, emphasizing its market leadership and future growth opportunities in a recent informational webinar.

Bio-Rad Laboratories announced solid second-quarter 2025 financial results, driven by revenue growth and improved operating margin, and raised its full-year financial outlook.

Bio-Rad Laboratories, Inc. announced the appointment of Rajat Mehta as Executive Vice President, Global Commercial Operations, succeeding the retiring Michael Crowley.

Bio-Rad Laboratories, Inc. has successfully completed the acquisition of all equity interests in Stilla Technologies, a French corporation, as previously announced.

Bio-Rad Laboratories announced its Q1 2025 financial results, showing a decrease in revenue but solid margins, and updated its full-year 2025 financial outlook due to market uncertainty.

Bio-Rad Laboratories held its annual meeting on April 22, 2025, where directors were elected, the selection of KPMG LLP as independent auditors was ratified, and a stockholder proposal regarding executive severance arrangements was not approved.

Bio-Rad Laboratories provides an update on its investment in Sartorius AG, summarizing Sartorius's financial data for the year ended December 31, 2024.

Bio-Rad Laboratories reported a decrease in revenue for Q4 and full-year 2024, initiated a restructuring plan to improve operating performance, and announced a binding offer to acquire Stilla Technologies.

Bio-Rad Laboratories announced a 2.8% increase in third-quarter sales, driven by clinical diagnostics, while facing headwinds in the life science sector.

Bio-Rad Laboratories updated its bylaws to allow for electronic stockholder meetings, streamline proxy procedures, and clarify officer roles.

Bio-Rad Laboratories has appointed Jonathan DiVincenzo as its new President and Chief Operating Officer, effective September 9, 2024, succeeding Andy Last who is retiring.

Bio-Rad Laboratories reported a decrease in second-quarter sales and a significant net loss due to changes in investment value, while also increasing its share repurchase program.

Bio-Rad Laboratories' first quarter 2024 results show a decline in overall sales driven by weakness in the life science sector, offset by growth in clinical diagnostics.

Bio-Rad Laboratories has announced the resignation of Simon May, President of the Life Science Group, and the appointment of James J. Barry as his successor, effective May 1, 2024, alongside the approval of an amended incentive award plan.

Bio-Rad Laboratories' Chief Operating Officer, Dr. Andrew Last, will retire by early September 2024, initiating a search for his successor.

Bio-Rad Laboratories has announced the appointment of Roop K. Lakkaraju as its new Executive Vice President and Chief Financial Officer, effective April 15, 2024.

Bio-Rad Laboratories has updated its investment information regarding Sartorius AG, following the release of Sartorius's 2023 financial results.

Bio-Rad Laboratories reported a decrease in fourth-quarter and full-year 2023 sales, impacted by biopharma market weakness, but anticipates a gradual recovery in the second half of 2024.

Bio-Rad Laboratories has entered into a new $200 million revolving credit agreement, replacing its previous facility and providing funds for acquisitions and working capital.